REFERENCES
1. Wang J.H., Skeans M.A., Israni A.K. Current status of kidney transplant outcomes: dying to survive. Adv Chronic Kidney Dis. 2016; 23 (5): 281–6. DOI: https://doi.org/10.1053/j.ackd.2016.07.001; PMID: 27742381.
2. Sultanov P.K., Hadzhibaev F.A., Ergashev D.N., Ismatov A.A. Analysis of complications after kidney transplantation: literature review. Vestnik ekstrennoy meditsiny [Bulletin of Emergency Medicine]. 2021; 14 (1): 55–64. (in Russian)
3. Gautier S.V., Khomyakov S.V. Organ donation and transplantation in the Russian Federation in 2019. 12th report on register of the Russian Transplant Society. Vestnik transplantologii i iskusstvennykh organov [Bulletin of Transplantology and Artificial Organs]. 2020; 22 (2): 8–34. DOI: https://doi.org/10.15825/1995-1191-2020-2-8-34 (in Russian)
4. Clinical practice guideline «Kidney transplantation, presence of a transplanted kidney, death and rejection of a kidney transplant», developed by «Russian Transplantological Society». 2020. (in Russian)
5. Lin H., Yan J., Yuan L., et al. Impact of diabetes mellitus developing after kidney transplantation on patient mortality and graft survival: a meta-analysis of adjusted data. Diabetol Metab Syndr. 2021; 13: 126. DOI: https://doi.org/10.1186/s13098-021-00742-4
6. Martirosyan S.M., Kosmacheva E.D. Prevalence of cardiovascular disease before and after kidney transplantation. Al’manakh klinicheskoy meditsiny [Almanac of Clinical Medicine]. 2017; 45 (7): 575–85. DOI: https://doi.org/10.18786/2072-0505-2017-45-7-575-585 (in Russian)
7. Sharif A., Hecking M., de Vries A.P., et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014; 14 (9): 1992–2000. DOI: https://doi.org/10.1111/ajt.12850; PMID: 25307034.
8. Dong M., Parsaik A.K., Eberhardt N.L., et al. Cellular and physiological mechanisms of new-onset diabetes mellitus after solid organ transplantation. Diabet Med. 2012; 29 (7): 1–12.
9. Dai C., Walker J.T., Shostak A., et al. Tacrolimus- and sirolimus-induced human β cell dysfunction is reversible and preventable. JCI Insight. 2020; 5 (1): e130770. DOI: https://doi.org/10.1172/jci.insight.130770
10. Balashova A.V., Mustafina V.R., Glinkina I.V. Interdisciplinary problem of post-transplant diabetes mellitus: literature review. Sechenovskiy vestnik [Sechenov Bulletin]. 2021; 12 (1): 60–73. DOI: https://doi.org/10.47093/2218-7332.2021.12.1.60-73 (in Russian)
11. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Transl. A. Denisov, ed. E. Zakharova. Nefrologiya i dializ. Prilozhenie [Nephrology and Dialysis. Supplement]. 2021; 23 (2): 9–121. DOI: https://doi.org/10.28996/2618-9801-2021-2suppl-9-121 (in Russian)
12. Montada-Atin T., Prasad G.V.R. Recent advances in new-onset diabetes mellitus after kidney transplantation. World J Diabetes. 2021; 12 (5): 541–55. DOI: https://doi.org/10.4239/wjd.v12.i5.541
13. Antsiferov M.B., Koteshkova O.M., Novikova M.S., Demidov N.A. Possibilities of dapagliflozin in cardio-renometabolic protections in patients with and without type 2 diabetes mellitus. Farmateka [Pharmateca]. 2021; 28 (12): 53–9. (in Russian)
14. Schwaiger E., Burghart L., Signorini L., et al. Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant. 2019; 19: 907–19. DOI: https://doi.org/10.1111/ajt.15223
15. Hecking M., Sharif A., Eller K., Jenssen T. Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics. Transplant Int. 2021; 34 (1): 27–48. DOI: https://doi.org/10.1111/tri.13783
16. Kanbay M., Demiray A., Afsar B., et al. Sodium-glucose cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: review of the current evidence. Nephrology. 2021; 26 (12): 1007–17. DOI: https://doi.org/10.1111/nep.13941